Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsy

Chan, Wah Kheong; Chong, Shi-En; Chang, Felicia; Lai, Lee‐Lee; Chuah, Kee Huat; Mustapha, Nik Raihan Nik; Mahadeva, Sanjiv; Chan, Wah‐Kheong

doi:10.1007/s12072-023-10550-9

Cited by 7 publications

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liver-related events occurred only in patients with advanced liver fibrosis (cumulative incidence 9.1% in patients with advanced liver fibrosis vs. 0% in patients without advanced liver fibrosis), with rates of a liver-related event of 1.47 and 3.85 per 100 person-years among patients with F3 and F4 fibrosis, respectively (F3 is bridging fibrosis on liver biopsy, while F4 is cirrhosis; fibrosis stage ≥F3 is considered advanced liver fibrosis). 20 …”

Section: Epidemiology Natural History and Burden Of Diseasementioning

confidence: 99%

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review

Chan,

Chuah,

Rajaram

et al. 2023

Journal of Obesity & Metabolic Syndrome

Self Cite

158

View full text Add to dashboard Cite

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the latest term for steatotic liver disease associated with metabolic syndrome. MASLD is the most common cause of chronic liver disease and is the leading cause of liver-related morbidity and mortality. It is important that all stakeholders be involved in tackling the public health threat of obesity and obesity-related diseases, including MASLD. A simple and clear assessment and referral pathway using non-invasive tests is essential to ensure that patients with severe MASLD are identified and referred to specialist care, while patients with less severe disease remain in primary care, where they are best managed. While lifestyle intervention is the cornerstone of the management of patients with MASLD, cardiovascular disease risk must be properly assessed and managed because cardiovascular disease is the leading cause of mortality. No pharmacological agent has been approved for the treatment of MASLD, but novel anti-hyperglycemic drugs appear to have benefit. Medications used for the treatment of diabetes and other metabolic conditions may need to be adjusted as liver disease progresses to cirrhosis, especially decompensated cirrhosis. Based on non-invasive tests, the concepts of compensated advanced chronic liver disease and clinically significant portal hypertension provide a practical approach to stratifying patients according to the risk of liver-related complications and can help manage such patients. Finally, prevention and management of sarcopenia should be considered in the management of patients with MASLD.

show abstract

Section: Epidemiology Natural History and Burden Of Diseasementioning

confidence: 99%

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review

Chan,

Chuah,

Rajaram

et al. 2023

Journal of Obesity & Metabolic Syndrome

Self Cite

158

View full text Add to dashboard Cite

show abstract

Editorial: The Impact of Socioeconomic and Ethnic Factors on Chronic Liver Disease

Chan,

Chuah

2024

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Chronic liver diseases (CLDs) are a global health concern of significant magnitude, yet their true impact is often underestimated [1]. These diseases contribute to approximately two million deaths each year, accounting for around 4% of all global fatalities [2]. Despite their prevalence, CLDs frequently receive less attention compared to other major health issues. A timely study by Lee et al. which included 59,204 adult participants, examines CLD trends in the United States and highlights the disparity in disease burden across socioeconomic groups. Notably, lowerincome communities face a higher burden of liver disease, with increased risks of overall CLDs (33%), hepatitis C virus (HCV) (75%), hepatitis B virus (HBV) (50%), advanced fibrosis (33%) and non-alcoholic fatty liver disease (NAFLD) (8%) compared to higher-income groups [3]. This disparity may be attributed to limited access to healthier lifestyle resources and healthcare facilities among lower-income populations [4].Ethnicity also plays a crucial role in the prevalence and distribution of CLDs (Figure 1). In the United States, different ethnic groups exhibit varying rates of liver diseases [5]. For example,

show abstract

Dipeptidyl peptidase‐4 inhibitor and sodium‐glucose cotransporter 2 inhibitor additively ameliorate hepatic steatosis through different mechanisms of action in high‐fat diet‐fed mice

Iwamoto,

Kimura,

Dan

et al. 2024

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

AimDipeptidyl peptidase‐4 (DPP‐4) inhibitors suppress the inactivation of incretin hormones and lower blood glucose levels by inhibiting DPP‐4 function. Sodium‐glucose cotransporter 2 (SGLT2) inhibitors lower blood glucose levels in an insulin‐independent manner by inhibiting renal reabsorption of glucose. DPP‐4 and SGLT2 inhibitors each have the potential to improve hepatic steatosis; however, their combined effects remain unclear. In this study, we examined the effects of the combination of these drugs on hepatic steatosis using high‐fat diet‐fed mice.MethodC57BL/6J male mice were fed a 60% high‐fat diet for 2 months to induce hepatic steatosis. Mice were divided into four groups (control; DPP‐4 inhibitor anagliptin; SGLT2 inhibitor luseogliflozin; anagliptin and luseogliflozin combination), and the effects of each drug and their combination on hepatic steatosis after a 4‐week intervention were evaluated.ResultsThere were no differences in blood glucose levels among the four groups. Anagliptin suppresses inflammation‐ and chemokine‐related gene expression. It also improved macrophage fractionation in the liver. Luseogliflozin reduced body weight, hepatic gluconeogenesis and blood glucose levels in the oral glucose tolerance test. The combination treatment improved hepatic steatosis without interfering with the effects of anagliptin and luseogliflozin, respectively, and fat content and inflammatory gene expression in the liver were significantly improved in the combination group compared with the other groups.ConclusionThe combination therapy with the DPP‐4 inhibitor anagliptin and the SGLT2 inhibitor luseogliflozin inhibits fat deposition in the liver via anti‐inflammatory effects during the early phase of diet‐induced liver steatosis.

show abstract

Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsy

Cited by 7 publications

References 45 publications

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review

Editorial: The Impact of Socioeconomic and Ethnic Factors on Chronic Liver Disease

Dipeptidyl peptidase‐4 inhibitor and sodium‐glucose cotransporter 2 inhibitor additively ameliorate hepatic steatosis through different mechanisms of action in high‐fat diet‐fed mice

Contact Info

Product

Resources

About